A Phase 3 interventional study of DTG/3TC FDC and CAR in HIV Infections, sponsored by ViiV Healthcare. Completed at 119 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-19.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.
Among the 55 studies testing dolutegravir in HIV Infections, this one is the 11th largest by enrollment, is one of 8 that started in 2019, is one of 21 in phase 3, and was the 38th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in Romania, South Africa, Uganda
José Antonio Mata Marín · Sites in Mexico
Ages 18–70
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
José Antonio Mata Marín · Sites in Mexico
Ages 18–70 · Men only
ViiV Healthcare · Sites in United States
Ages 6–12
By country, each count listing its studies:
Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 24 · Phase 4 11
First in 2009; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 493 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 126 across the 55 interventional studies. Of the 43 that completed or were terminated, 26 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 26th largest by enrollment of the 210 interventional ones that give a count, is one of 14 that started in 2019, is one of 65 in phase 3, and was the 205th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing dolutegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 55 studies testing dolutegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to determine if virologically suppressed Human Immunodeficiency Virus (HIV) Type 1 infected adults on a current antiretroviral regimen (CAR) (including 2 nucleoside reverse transcriptase inhibitors [NRTIs] plus a third agent) remain suppressed upon switching to dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC). The main objective of the study is to demonstrate the non-inferior antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks in virologically suppressed adults living with HIV-1. The study will also evaluate information regarding the safety and health related quality of life. The study will include Screening Phase (up to 28 days), a Randomization Phase (up to Week 52) and a Continuation Phase (post Week 52). The Continuation Phase is not applicable for participants in Sweden and Denmark. Approximately 490 participants will be randomized in 1:1 ratio to receive DTG/3TC FDC once daily for up to 52 weeks or continue their CAR for 52 weeks. Participants in the DTG/3TC FDC arm who successfully complete up to 52 weeks of treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in Continuation Phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant must be on uninterrupted current regimen (either the initial or second Combination antiretroviral therapy [cART] regimen) for at least 3 months prior to Screening.
i) Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability and/or safety concerns or access to medications, or convenience/simplification and must not have been done for suspected or established treatment failure. The following switches, if they are the only switches, would not be considered a change in regimen. a) A switch from a PI boosted with ritonavir (RTV) to the same PI boosted with cobicistat is allowed (and vice versa). b) A switch from 3TC to emtricitabine (FTC) (and vice versa). c) A switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) (and vice versa).
ii) Acceptable stable cART regimens prior to Screening include 2 NRTIs plus a) INI (either the initial or second cART regimen) b) NNRTI (either the initial or second cART regimen) c) Boosted PI (or atazanavir [ATV] unboosted) (either the initial or second PI-based cART regimen).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will be randomized to receive 50 milligrams (mg)/300 mg DTG/3TC FDC therapy from Day 1 up to 52 weeks. Participants who complete 52 weeks of treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in the continuation phase.
Drug: DTG/3TC FDC
Eligible participants will continue to receive CAR from Day 1 up to 52 weeks.
Drug: CAR
Drug pages: Dolutegravir · Lamivudine
DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.
Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) >=50 Copies/Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Category at Week 48
Number of participants with plasma HIV 1 RNA \>=50 c/mL were evaluated using FDA snapshot algorithm at Week 48 to demonstrate the non-inferior antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \>=50 c/mL were termed as subjects with virologic failure. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
Time frame: Week 48
Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 48
Number of participants with plasma HIV 1 RNA \<50 c/mL were evaluated using FDA snapshot algorithm at Week 48 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \<50 c/mL were termed as subjects with virologic success. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
Time frame: Week 48
Number of Participants With Plasma HIV-1 RNA >=50 c/mL as Per FDA Snapshot Category at Week 24
Number of participants with plasma HIV 1 RNA \>=50 c/mL were evaluated using FDA snapshot algorithm at Week 24 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 24 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \>=50 c/mL were termed as subjects with virologic failure. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
Time frame: Week 24
Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 24
Number of participants with plasma HIV 1 RNA \<50 c/mL were evaluated using FDA snapshot algorithm at Week 24 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 24 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \<50 c/mL were termed as subjects with virologic success. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
Time frame: Week 24
Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count for Week 24
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+ lymphocyte count was assessed at Week 24 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in CD4+ Cell Count for Week 48
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+ lymphocyte count was assessed at Week 48 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.
Time frame: Baseline (Day 1) and Week 48
Change From Baseline in CD4+/ Cluster of Differentiation 8 (CD8+) Cell Counts Ratio for Week 24
CD4+/CD8+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+/CD8+ lymphocyte cell count ratio was assessed at Week 24 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in CD4+/CD8+ Cell Counts Ratio for Week 48
CD4+/CD8+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+/CD8+ lymphocyte cell count ratio was assessed at Week 48 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.
Time frame: Baseline (Day 1) and Week 48
Number of Participants With Disease Progression Through Week 24
Participants with disease progression included incidences of HIV-associated conditions, Acquired Immuno Deficiency Syndrome (AIDS) and death. HIV-associated conditions were assessed according to the 2014 HIV infection by Centers for Disease Control and Prevention (CDC) classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC once daily compared to continuation of CAR.
Time frame: Up to Week 24
Number of Participants With Disease Progression Through Week 48
Participants with disease progression included incidences of HIV-associated conditions, AIDS and death. HIV-associated conditions were assessed according to the 2014 HIV infection by CDC classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC once daily compared to continuation of CAR.
Time frame: Up to Week 48
Number of Participants With Adverse Events (AEs) and AEs Leading to Discontinuation
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
Time frame: Up to Week 52
Number of Participants With AEs by Severity Grades
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms
Time frame: Up to 52 weeks
Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks
Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.
Time frame: Up to Week 52
Number of Participants With Any AEs and AEs by Severity Grades for Those Participants With Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with any AE were presented and AEs were graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms.
Time frame: Up to 52 weeks
Number of Participants With Any AEs and AEs by Severity Grades for Those Participants With Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with any AE were presented and AEs were graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms.
Time frame: Up to 52 weeks
Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
Time frame: Up to 52 weeks
Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
Time frame: Up to 52 weeks
Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2
Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.
Time frame: Up to Week 52
Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2
Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.
Time frame: Up to Week 52
Change From Baseline in Fasting Lipids at Week 24
Lipid parameters included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Fasting Lipids at Week 48
Lipid parameters included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides.
Time frame: Baseline (Day 1) and Week 48
Number of Participants With Observed Genotypic and Phenotypic Resistance to Antiretrovirals (ARVs) for Participants Meeting Confirmed Virologic Withdrawal (CVW) Criteria
Genotypic and phenotypic testing was conducted for participants who met the CVW criteria, i.e., one assessment with HIV-1 RNA ≥200 c/mL after Day 1 with an immediately prior HIV-1 RNA ≥50 c/mL at any point in the study.
Time frame: Up to week 48
Change From Baseline in Health Status by HIV Treatment Satisfaction Questionnaire (TSQ) at Week 24
The HIV Treatment Satisfaction Questionnaire (HIVTSQ) is a 10-item self-reported scale that consists of a total score ranging from 0 to 60. Higher scores indicate a greater level of patient-reported satisfaction with their current therapy.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Health Status by HIV TSQ at Week 48
The HIVTSQ is a 10-item self-reported scale that consists of a total score ranging from 0 to 60. Higher scores indicate a greater level of patient-reported satisfaction with their current therapy.
Time frame: Baseline (Day 1) and Week 48
Change From Baseline in Health Status by Symptom Distress Module (SDM) at Week 24
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Health Status by SDM at Week 48
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).
Time frame: Baseline (Day 1) and Week 48
Change From Baseline in Health Status by SDM in Continuation Phase
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).
Time frame: Baseline (Day 1) and Week 76, Week 100, and Week 132
The study consist of two phases - Randomized phase and Continuation phase.
| Milestone | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR | Continuation Phase-Participants Who Received DTG/3TC FDC |
|---|---|---|---|
| Started | 246 | 247 | 0 |
| Completed | 136 | 229 | 0 |
| Not completed | 110 | 18 | 0 |
| Withdrew: Adverse event | 4 | 3 | 0 |
| Withdrew: Lack of efficacy | 0 | 3 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 5 | 0 |
| Withdrew: Transferred to continuation phase | 96 | 0 | 0 |
| Withdrew: Protocol deviation | 5 | 4 | 0 |
| Milestone | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR | Continuation Phase-Participants Who Received DTG/3TC FDC |
|---|---|---|---|
| Started | 0 | 0 | 96 |
| Completed | 0 | 0 | 91 |
| Not completed | 0 | 0 | 5 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 2 |
Number of participants with plasma HIV 1 RNA \>=50 c/mL were evaluated using FDA snapshot algorithm at Week 48 to demonstrate the non-inferior antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \>=50 c/mL were termed as subjects with virologic failure. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) >=50 Copies/Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Category at Week 48 | 1 | 3 |
Number of participants with plasma HIV 1 RNA \<50 c/mL were evaluated using FDA snapshot algorithm at Week 48 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \<50 c/mL were termed as subjects with virologic success. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 48 | 232 | 229 |
Number of participants with plasma HIV 1 RNA \>=50 c/mL were evaluated using FDA snapshot algorithm at Week 24 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 24 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \>=50 c/mL were termed as subjects with virologic failure. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Number of Participants With Plasma HIV-1 RNA >=50 c/mL as Per FDA Snapshot Category at Week 24 | 0 | 1 |
Number of participants with plasma HIV 1 RNA \<50 c/mL were evaluated using FDA snapshot algorithm at Week 24 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 24 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \<50 c/mL were termed as subjects with virologic success. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 24 | 234 | 237 |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+ lymphocyte count was assessed at Week 24 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.
| cells/cubic millimeter (cells/mm^3) | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count for Week 24 | 30.5 (-71.5 to 111) | 10 (-79 to 95) |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+ lymphocyte count was assessed at Week 48 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.
| cells/mm^3 | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Change From Baseline in CD4+ Cell Count for Week 48 | 30 (-83 to 115.5) | 2 (-105 to 94) |
CD4+/CD8+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+/CD8+ lymphocyte cell count ratio was assessed at Week 24 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.
| Ratio | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Change From Baseline in CD4+/ Cluster of Differentiation 8 (CD8+) Cell Counts Ratio for Week 24 | -0.02 (-0.105 to 0.07) | 0.01 (-0.06 to 0.09) |
CD4+/CD8+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+/CD8+ lymphocyte cell count ratio was assessed at Week 48 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.
| Ratio | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Change From Baseline in CD4+/CD8+ Cell Counts Ratio for Week 48 | 0.04 (-0.06 to 0.13) | 0.05 (-0.06 to 0.13) |
Participants with disease progression included incidences of HIV-associated conditions, Acquired Immuno Deficiency Syndrome (AIDS) and death. HIV-associated conditions were assessed according to the 2014 HIV infection by Centers for Disease Control and Prevention (CDC) classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC once daily compared to continuation of CAR.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Number of Participants With Disease Progression Through Week 24 | 0 | 0 |
Participants with disease progression included incidences of HIV-associated conditions, AIDS and death. HIV-associated conditions were assessed according to the 2014 HIV infection by CDC classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC once daily compared to continuation of CAR.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Number of Participants With Disease Progression Through Week 48 | 1 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| AEs | 180 | 172 |
| AEs leading to discontinuation | 5 | 3 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Grade 1 | 92 | 67 |
| Grade 2 | 77 | 86 |
| Grade 3 | 10 | 17 |
| Grade 4 | 0 | 2 |
| Grade 5 | 1 | 0 |
Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| ALT >=3xUpper Limit of Normal (ULN) & BIL >=2xULN | 0 | 0 |
| ALT >=3xULN & ALP <2xULN & BIL >=2xULN | 0 | 0 |
| ALT >=3xULN & BIL >=1.5xULN | 0 | 0 |
| AST >=3xULN & BIL >=2xULN | 0 | 0 |
| AST >=3xULN & ALP <2xULN & BIL >=2xULN | 0 | 0 |
| AST >=3xULN & BIL >=1.5xULN | 0 | 0 |
| ALT+AST >=20xULN | 0 | 0 |
| ALT+AST >=10xULN | 0 | 0 |
| ALT+AST >=5xULN | 0 | 0 |
| ALT+AST >=3xULN | 3 | 2 |
| ALT >=20xULN | 0 | 0 |
| ALT >=10xULN | 0 | 0 |
| ALT >=5xULN | 1 | 1 |
| ALT >=3xULN | 6 | 5 |
| AST >=20xULN | 0 | 0 |
| AST >=10xULN | 0 | 0 |
| AST >=5xULN | 1 | 0 |
| AST >=3xULN | 5 | 2 |
| BIL >=2xULN | 0 | 5 |
| BIL >=1.5xULN | 0 | 7 |
| ALP >=1.5xULN | 4 | 8 |
| ALT >=3xULN - <5xULN | 5 | 4 |
| ALT >=5xULN - <10xULN | 1 | 1 |
| ALT >=10xULN - <20xULN | 0 | 0 |
| Hepatocellular injury | 5 | 1 |
| Hepatocellular injury and BIL >=2xULN | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with any AE were presented and AEs were graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Any Event | 1 | 3 |
| Grade 1 | 1 | 1 |
| Grade 2 | 0 | 2 |
| Grade 3 | 0 | 0 |
| Grade 4 | 0 | 0 |
| Grade 5 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with any AE were presented and AEs were graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Any Event | 179 | 169 |
| Grade 1 | 91 | 66 |
| Grade 2 | 77 | 84 |
| Grade 3 | 10 | 17 |
| Grade 4 | 0 | 2 |
| Grade 5 | 1 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2 | 0 | 1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2 | 5 | 2 |
Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| ALT >=3xUpper Limit of Normal (ULN) & BIL >=2xULN | 0 | 0 |
| ALT >=3xULN & ALP <2xULN & BIL >=2xULN | 0 | 0 |
| ALT >=3xULN & BIL >=1.5xULN | 0 | 0 |
| AST >=3xULN & BIL >=2xULN | 0 | 0 |
| AST >=3xULN & ALP <2xULN & BIL >=2xULN | 0 | 0 |
| AST >=3xULN & BIL >=1.5xULN | 0 | 0 |
| ALT+AST >=20xULN | 0 | 0 |
| ALT+AST >=10xULN | 0 | 0 |
| ALT+AST >=5xULN | 0 | 0 |
| ALT+AST >=3xULN | 0 | 0 |
| ALT >=20xULN | 0 | 0 |
| ALT >=10xULN | 0 | 0 |
| ALT >=5xULN | 0 | 0 |
| ALT >=3xULN | 0 | 0 |
| AST >=20xULN | 0 | 0 |
| AST >=10xULN | 0 | 0 |
| AST >=5xULN | 0 | 0 |
| AST >=3xULN | 0 | 0 |
| BIL >=2xULN | 0 | 1 |
| BIL >=1.5xULN | 0 | 1 |
| ALP >=1.5xULN | 0 | 0 |
| ALT >=3xULN - <5xULN | 0 | 0 |
| ALT >=5xULN - <10xULN | 0 | 0 |
| ALT >=10xULN - <20xULN | 0 | 0 |
| Hepatocellular injury | 0 | 0 |
| Hepatocellular injury and BIL >=2xULN | 0 | 0 |
Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.
| Participants | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| ALT >=3xUpper Limit of Normal (ULN) & BIL >=2xULN | 0 | 0 |
| ALT >=3xULN & ALP <2xULN & BIL >=2xULN | 0 | 0 |
| ALT >=3xULN & BIL >=1.5xULN | 0 | 0 |
| AST >=3xULN & BIL >=2xULN | 0 | 0 |
| AST >=3xULN & ALP <2xULN & BIL >=2xULN | 0 | 0 |
| AST >=3xULN & BIL >=1.5xULN | 0 | 0 |
| ALT+AST >=20xULN | 0 | 0 |
| ALT+AST >=10xULN | 0 | 0 |
| ALT+AST >=5xULN | 0 | 0 |
| ALT+AST >=3xULN | 3 | 2 |
| ALT >=20xULN | 0 | 0 |
| ALT >=10xULN | 0 | 0 |
| ALT >=5xULN | 1 | 1 |
| ALT >=3xULN | 6 | 5 |
| AST >=20xULN | 0 | 0 |
| AST >=10xULN | 0 | 0 |
| AST >=5xULN | 1 | 0 |
| AST >=3xULN | 5 | 2 |
| BIL >=2xULN | 0 | 4 |
| BIL >=1.5xULN | 0 | 6 |
| ALP >=1.5xULN | 4 | 8 |
| ALT >=3xULN - <5xULN | 5 | 4 |
| ALT >=5xULN - <10xULN | 1 | 1 |
| ALT >=10xULN - <20xULN | 0 | 0 |
| Hepatocellular injury | 5 | 1 |
| Hepatocellular injury and BIL >=2xULN | 0 | 0 |
Lipid parameters included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides.
| milligram/deciliter (mg/dL) | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Serum or Plasma Triglycerides (mg/dL) | -4.944 ± 56.4947 | -3.571 ± 61.9494 |
| Serum or Plasma HDL Cholesterol, Direct (mg/dL) | -0.326 ± 9.1737 | 0.585 ± 8.3277 |
| Serum or Plasma Cholesterol (mg/dL) | -3.096 ± 31.6634 | 0.058 ± 25.8019 |
| Serum or Plasma LDL Cholesterol (Calculated or Direct), (mg/dL) | -1.64 ± 25.5153 | -0.06 ± 19.802 |
Lipid parameters included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides.
| mg/dL | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Serum or Plasma Triglycerides (mg/dL) | -3.112 ± 66.9065 | -4.002 ± 71.0132 |
| Serum or Plasma HDL Cholesterol, Direct (mg/dL) | -0.809 ± 10.5651 | 0.688 ± 8.5584 |
| Serum or Plasma Cholesterol (mg/dL) | 0.131 ± 30.271 | 2.668 ± 27.0351 |
| Serum or Plasma LDL Cholesterol (Calculated or Direct), (mg/dL) | 1.753 ± 22.8585 | 2.734 ± 20.0256 |
Genotypic and phenotypic testing was conducted for participants who met the CVW criteria, i.e., one assessment with HIV-1 RNA ≥200 c/mL after Day 1 with an immediately prior HIV-1 RNA ≥50 c/mL at any point in the study.
No measurements were reported for this outcome.
The HIV Treatment Satisfaction Questionnaire (HIVTSQ) is a 10-item self-reported scale that consists of a total score ranging from 0 to 60. Higher scores indicate a greater level of patient-reported satisfaction with their current therapy.
| Scores on a scale | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Change From Baseline in Health Status by HIV Treatment Satisfaction Questionnaire (TSQ) at Week 24 | 2.9 ± 5.85 | 1 ± 5.16 |
The HIVTSQ is a 10-item self-reported scale that consists of a total score ranging from 0 to 60. Higher scores indicate a greater level of patient-reported satisfaction with their current therapy.
| Scores on a scale | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Change From Baseline in Health Status by HIV TSQ at Week 48 | 2.9 ± 6 | 1 ± 5.14 |
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).
| Scores on a scale | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Change From Baseline in Health Status by Symptom Distress Module (SDM) at Week 24 | -2.6 ± 8.69 | -0.7 ± 8.01 |
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).
| Scores on a scale | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR |
|---|---|---|
| Change From Baseline in Health Status by SDM at Week 48 | -2.4 ± 7.64 | -1.5 ± 7.92 |
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).
| Scores on a scale | Continuation Phase-Participants Who Received DTG/3TC FDC |
|---|---|
| Week 76 | -4.1 ± 8.69 |
| Week 100 | -3.4 ± 11.33 |
| Week 132 | -6.1 ± 9.94 |
Collected over All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected from day 1 to week 52 for Randomized Phase and from week 52 to week 132 for continuation phase.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Phase-Participants Who Received DTG/3TC FDC | 1/246 (0.4%) | 7/246 (2.8%) | 179/246 (72.8%) |
| Randomized Phase-Participants Who Received CAR | 0/247 (0%) | 16/247 (6.5%) | 169/247 (68.4%) |
| Continuation Phase-Participants Who Received DTG/3TC FDC | 0/96 (0%) | 1/96 (1%) | 43/96 (44.8%) |
| Event | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR | Continuation Phase-Participants Who Received DTG/3TC FDC |
|---|---|---|---|
| COVID-19Infections and infestations | 1/246 | 3/247 | 0/96 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/246 | 0/247 | 1/96 |
| Pneumonia bacterialInfections and infestations | 0/246 | 2/247 | 0/96 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/246 | 0/247 | 0/96 |
| Anal abscessInfections and infestations | 1/246 | 0/247 | 0/96 |
| CataractEye disorders | 1/246 | 0/247 | 0/96 |
| DeathGeneral disorders | 1/246 | 0/247 | 0/96 |
| Gastrointestinal stromal tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/246 | 0/247 | 0/96 |
| TracheitisInfections and infestations | 1/246 | 0/247 | 0/96 |
| Acute myocardial infarctionCardiac disorders | 0/246 | 1/247 | 0/96 |
| Event | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR | Continuation Phase-Participants Who Received DTG/3TC FDC |
|---|---|---|---|
| Weight increasedInvestigations | 20/246 | 5/247 | 3/96 |
| HeadacheNervous system disorders | 16/246 | 17/247 | 3/96 |
| Upper respiratory tract infectionInfections and infestations | 11/246 | 15/247 | 3/96 |
| COVID-19Infections and infestations | 14/246 | 8/247 | 3/96 |
| Back painMusculoskeletal and connective tissue disorders | 14/246 | 7/247 | 3/96 |
| InsomniaPsychiatric disorders | 14/246 | 4/247 | 1/96 |
| DizzinessNervous system disorders | 13/246 | 6/247 | 1/96 |
| AnxietyPsychiatric disorders | 5/246 | 6/247 | 5/96 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 3/246 | 3/247 | 5/96 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 1/246 | 5/247 | 5/96 |
| Age, Continuous(YEARS) | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR | Total |
|---|---|---|---|
| Mean | 45.5 ± 11.04 | 45.8 ± 11.99 | 45.7 ± 11.51 |
| Sex: Female, Male(Participants) | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR | Total |
|---|---|---|---|
| Female | 108 | 84 | 192 |
| Male | 138 | 163 | 301 |
| Race/Ethnicity, Customized(Participants) | Randomized Phase-Participants Who Received DTG/3TC FDC | Randomized Phase-Participants Who Received CAR | Total |
|---|---|---|---|
| African American/African Heritage | 45 | 48 | 93 |
| American Indian OR Alaska Native | 18 | 14 | 32 |
| Asian - East Asian Heritage | 27 | 36 | 63 |
| Asian - South East Asian Heritage | 4 | 3 | 7 |
| White - Arabic/North African Heritage | 7 | 4 | 11 |
| White - White/Caucasian/European Heritage | 142 | 140 | 282 |
| Multiple | 3 | 2 | 5 |
Showing the first 100 of 119 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Nov 2019 to primary completion in Apr 2021, 17 months.
Results were first posted in Jul 2022, 1 year 2 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 17 months is below that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dolutegravir · Lamivudine